Kozak & Associates’s Fulgent Genetics FLGT Stock Holding History

Kozak & Associates’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-65	Closed	-$1.87K	–	443
2025 Q3	$1.87K	Hold	65	–	–	﹤0.01%	383
2025 Q2	$1.27K	Hold	65	–	–	﹤0.01%	368
2025 Q1	$1.23K	Hold	65	–	–	﹤0.01%	381
2024 Q4	$1.22K	Hold	65	–	–	﹤0.01%	378
2024 Q3	$1.31K	Hold	65	–	–	﹤0.01%	345
2024 Q2	$1.29K	Hold	65	–	–	﹤0.01%	339
2024 Q1	$1.46K	Hold	65	–	–	﹤0.01%	342
2023 Q4	$1.72K	Hold	65	–	–	﹤0.01%	321
2023 Q3	$1.75K	Hold	65	–	–	﹤0.01%	337
2023 Q2	$2.37K	Hold	65	–	–	﹤0.01%	300
2023 Q1	$2.03K	Hold	65	–	–	﹤0.01%	308
2022 Q4	$2K	Hold	65	–	–	﹤0.01%	300
2022 Q3	$2K	Hold	65	–	–	﹤0.01%	296
2022 Q2	$4K	Hold	65	–	–	﹤0.01%	301
2022 Q1	$4K	Hold	65	–	–	﹤0.01%	321
2021 Q4	$4K	Hold	65	–	–	﹤0.01%	321
2021 Q3	$6K	Buy	+65	New	+$5.91K	﹤0.01%	269

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kozak & Associates's FLGT Position: Q4 2025 in Review

Kozak & Associates sold out of Fulgent Genetics (FLGT) in Q4 2025, closing a stake of 65 shares — an estimated $1.87K sold.

Kozak & Associates first reported a position in FLGT in Q3 2021 and held it in 17 quarters. The position peaked at $6K in Q3 2021. 179 funds tracked by Wall St. Rank hold FLGT as of Q4 2025.

Kozak & Associates reported no remaining Fulgent Genetics position as of Q4 2025 after selling out during the quarter.
Kozak & Associates sold 65 Fulgent Genetics shares in Q4 2025, an estimated $1.87K.
Kozak & Associates first reported a position in Fulgent Genetics in Q3 2021 and held it in 17 quarters.
Kozak & Associates's Fulgent Genetics position peaked at $6K in Q3 2021.
179 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2025.

Based on Kozak & Associates's 13F filing for Q4 2025, filed 12 Jan 2026.